Late Right Heart Failure After Left Ventricular Assist Device Implantation: Contemporary Insights and Future Perspectives
- PMID: 37269258
- DOI: 10.1016/j.jchf.2023.04.014
Late Right Heart Failure After Left Ventricular Assist Device Implantation: Contemporary Insights and Future Perspectives
Erratum in
-
Correction.JACC Heart Fail. 2023 Aug;11(8 Pt 1):1035. doi: 10.1016/j.jchf.2023.06.007. JACC Heart Fail. 2023. PMID: 37558384 No abstract available.
Abstract
Late right heart failure (RHF) is increasingly recognized in patients with long-term left ventricular assist device (LVAD) support and is associated with decreased survival and increased incidence of adverse events such as gastrointestinal bleeding and stroke. Progression of right ventricular (RV) dysfunction to clinical syndrome of late RHF in patients supported with LVAD is dependent on the severity of pre-existing RV dysfunction, persistent or worsening left- or right-sided valvular heart disease, pulmonary hypertension, inadequate or excessive left ventricular unloading, and/or progression of the underlying cardiac disease. RHF likely represents a continuum of risk with early presentation and progression to late RHF. However, de novo RHF develops in a subset of patients leading to increased diuretic requirement, arrhythmias, renal and hepatic dysfunction, and heart failure hospitalizations. The distinction between isolated late RHF and RHF due to left-sided contributions is lacking in registry studies and should be the focus of future registry data collection. Potential management strategies include optimization of RV preload and afterload, neurohormonal blockade, LVAD speed optimization, and treatment of concomitant valvular disease. In this review, the authors discuss definition, pathophysiology, prevention, and management of late RHF.
Keywords: late right heart failure; left ventricular assist device; mitral regurgitation; pulmonary hypertension; tricuspid regurgitation.
Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Funding Support and Author Disclosures Dr Tedford has consulting relationships with Medtronic, Abbott, Aria CV Inc, Alleviant, Acceleron, Cytokinetics, Itamar, Edwards Lifesciences, Eidos Therapeutics, Lexicon Pharmaceuticals, Gradient, and United Therapeutics; is on a steering committee for Acceleron/Merck and Abbott; is on a research advisory board for Abiomed; and performs hemodynamic core lab work for Merck. Dr Wieselthaler is a consultant for Medtronic. Dr Rame is a consultant for Actelion Pharmaceuticals and Abbott; was a steering committee member for the SOPRANO study; and was a coinvestigator for the RESTAGE trial. Dr Caliskan is a scientific advisory board member for FineHeart. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Similar articles
-
Preimplant Phosphodiesterase-5 Inhibitor Use Is Associated With Higher Rates of Severe Early Right Heart Failure After Left Ventricular Assist Device Implantation.Circ Heart Fail. 2019 Jun;12(6):e005537. doi: 10.1161/CIRCHEARTFAILURE.118.005537. Epub 2019 Jun 11. Circ Heart Fail. 2019. PMID: 31181953 Free PMC article.
-
Right ventricular response to pulsatile load is associated with early right heart failure and mortality after left ventricular assist device.J Heart Lung Transplant. 2017 Jan;36(1):97-105. doi: 10.1016/j.healun.2016.06.015. Epub 2016 Jun 24. J Heart Lung Transplant. 2017. PMID: 27469015
-
Incidence and clinical significance of late right heart failure during continuous-flow left ventricular assist device support.J Heart Lung Transplant. 2015 Aug;34(8):1024-32. doi: 10.1016/j.healun.2015.03.011. Epub 2015 Mar 26. J Heart Lung Transplant. 2015. PMID: 25935438
-
Mechanical circulatory support for the right ventricle in combination with a left ventricular assist device.Expert Rev Med Devices. 2019 Aug;16(8):663-673. doi: 10.1080/17434440.2019.1635006. Epub 2019 Jul 1. Expert Rev Med Devices. 2019. PMID: 31216915 Review.
-
Late-onset right ventricular failure after continuous-flow left ventricular assist device implantation: case presentation and review of the literature.J Cardiol. 2022 Aug;80(2):110-115. doi: 10.1016/j.jjcc.2021.12.009. Epub 2021 Dec 30. J Cardiol. 2022. PMID: 34974940 Review.
Cited by
-
Novel Therapies for Right Ventricular Failure.Curr Cardiol Rep. 2025 Jan 18;27(1):26. doi: 10.1007/s11886-024-02157-9. Curr Cardiol Rep. 2025. PMID: 39825962 Review.
-
Occult right ventricular dysfunction and right ventricular-vascular uncoupling in left ventricular assist device recipients.J Heart Lung Transplant. 2024 Apr;43(4):594-603. doi: 10.1016/j.healun.2023.11.015. Epub 2023 Nov 28. J Heart Lung Transplant. 2024. PMID: 38036276 Free PMC article.
-
Contemporary Evidence and Practice on Right Heart Catheterization in Patients with Acute or Chronic Heart Failure.Diagnostics (Basel). 2024 Jan 7;14(2):136. doi: 10.3390/diagnostics14020136. Diagnostics (Basel). 2024. PMID: 38248013 Free PMC article. Review.
-
Catheter Ablation for Tachyarrhythmias in Left Ventricular Assist Device Recipients: Clinical Significance and Technical Tips.J Clin Med. 2023 Nov 15;12(22):7111. doi: 10.3390/jcm12227111. J Clin Med. 2023. PMID: 38002723 Free PMC article. Review.
-
Metabolic Consequences of Advanced Chronic Heart Failure and its Modification by Implantation of a Durable Left Ventricular Assist Device.Rev Cardiovasc Med. 2024 Oct 31;25(11):388. doi: 10.31083/j.rcm2511388. eCollection 2024 Nov. Rev Cardiovasc Med. 2024. PMID: 39618874 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical